Download presentation
Presentation is loading. Please wait.
Published byMarsha Mitchell Modified over 9 years ago
1
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA) Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD
2
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Aim – Describe COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. Relevance – With improved survivability following cancer treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.
3
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Method COMP-VA is designed to be administered on chemo- therapy treatment unit just before treatment (chairside). – Uses portable ototoxicity identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.
4
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Clinical Objectives Pretreatment ototoxicity risk assessment. Behavioral screening for early hearing changes. Screening for outer hair cell dysfunction. Nonbehavioral screening for early hearing changes. Screen failure follow-up testing. Screening for tinnitus. Patient and provider education about ototoxic- induced hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.
5
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092 Slideshow Project DOI:10.1682/JRRD.2013.04.0092JSP Conclusion Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the- minute estimates of ototoxicity before patient’s next treatment. – This allows for timely consideration of treatment changes. Program encourages efficient communication and team relationships between audiology and oncology.
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.